In conclusion, our findings provide evidence of the effectiveness associated with first-line pembrolizumab plus pemetrexed-carboplatin in US oncology clinics for patients with good performance status and metastatic nonsquamous NSCLC without EGFR or ALK genomic aberrations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.